U.S., March 5 -- ClinicalTrials.gov registry received information related to the study (NCT07449234) titled 'A Study of Guselkumab After Switching From Ustekinumab in Participants With Moderate to Severe Psoriasis' on Feb. 27.
Brief Summary: The purpose of this study is to assess the effectiveness and safety of guselkumab following a switch from ustekinumab or an ustekinumab biosimilar in participants with moderate to severe psoriasis, a chronic inflammatory skin disease characterized by erythematous, scaly plaques that may be associated with pain and pruritus, in routine clinical practice.
Study Start Date: Feb. 09
Study Type: OBSERVATIONAL
Condition:
Psoriasis
Recruitment Status: RECRUITING
Sponsor: Janssen-Cilag Ltd.
Published by...